UNSPSC 51241553: Sodium chloride/sodium phosphate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.

UNSPSC 51241553 Sodium chloride/sodium phosphate (Commodity) encompasses generic and over-the-counter pharmaceutical products that state and local governments procure through cooperative purchasing arrangements and multistate alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively solicits manufacturers and suppliers of generic pharmaceuticals and OTC products for distribution across participating state and local government facilities. The procurement targets manufacturers capable of supplying comprehensive product lines with detailed specification data including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, and packaging configurations. Vendors must maintain contractual relationships with authorized wholesalers, comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and demonstrate pricing flexibility through multiple formats such as flat price, net price structures, or WAC-minus configurations. Suppliers are required to carry insurance coverage including commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and all products must meet FDA requirements with minimum one-year expiration dates and six-month shelf life from purchase.

MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026, represents the primary recent solicitation activity under this code. The solicitation encompasses Minnesota and participating states including Oregon through a cooperative purchasing vehicle. Awarded vendors will be provided to three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—effective July 1, 2026. Evaluation criteria weight price competitiveness at 75 percent, with remaining points distributed across fixed pricing, administrative fee compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term is two years for new vendors with optional extensions at MMCAP's discretion, while incumbent vendors' amendments extend through June 30, 2028. Performance penalties ranging from $200 to $1,500 per violation apply for late reporting, missed onboarding timelines, and improper class-of-trade denials.